European Journal of Clinical Pharmacology

, Volume 68, Issue 4, pp 441–448 | Cite as

Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis

  • Fabiola Del Santo
  • Dario Maratea
  • Valeria Fadda
  • Sabrina Trippoli
  • Andrea Messori
Short Communication

Abstract

Objectives

Oral drugs for relapsing–remitting multiple sclerosis (RRMS) have been recently investigated and, one of these, fingolimod, is already available in several countries. In this framework, an analysis of the data in terms of the comparative effectiveness for all treatments thus far approved for RRMS can be useful to reappraise their place in therapy.

Methods

After a MEDLINE search, we selected all randomised trials studying the effectiveness of drugs for RRMS and included in our analysis those randomised trials in which interferon, glatiramer, natalizumab or fingolimod were studied. The end-point was the relapse-free rate at 12 months, which was compared between the various treatments. Direct comparisons, based on actual randomised trials, were handled by calculating the trial-specific hazard ratio (HR) or the meta-analytic value of HR (when at least 2 trials were available). Indirect comparisons for which data from actual trials were missing were instead managed through a network meta-analysis.

Results

Ten randomised trials met the criteria set for our analysis. All active treatments were found to be significantly more effective than placebo (direct comparisons) in terms of freedom from relapse at the 12-month follow-up assessments; the values of HR ranged from 1.28 for glatiramer to 1.53 for interferon beta. The comparisons between active agents revealed that fingolimod was superior to interferon (HR = 1.18; direct comparison) and glatiramer (HR = 1.23; indirect comparison), while the other four head-to-head comparisons of treatments revealed no significant difference.

Conclusions

On the basis of the effectiveness data presently available, fingolimod seems to offer the advantage of oral administration together with the most favorable profile in terms of relapse-free rate at the 1-year follow-up assessment.

Keywords

Relapsing–remitting multiple sclerosis Network meta-analysis Interferon Glatiramer Natalizumab Fingolimod 

References

  1. 1.
    Plosker GL (2011) Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs 25(1):67–88PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen JA (2009) Emerging therapies for relapsing multiple sclerosis. Arch Neurol 66(7):821–828PubMedCrossRefGoogle Scholar
  3. 3.
    Caldwell DM, Ades AE, Higgins JPT (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J 331:897–900CrossRefGoogle Scholar
  4. 4.
    Fadda V, Maratea D, Trippoli S, Messori A (2011) Network meta-analysis. Results can be summarised in a simple figure. Br Med J 342:d1555. doi:10.1136/bmj.d1555 CrossRefGoogle Scholar
  5. 5.
    Messori A, Del Santo F, Maratea D (2011) First-line treatments for hepatitis C. Aliment Pharmacol Ther 33:1383–1385PubMedCrossRefGoogle Scholar
  6. 6.
    Fadda V, Maratea D, Trippoli S, Messori A (2011) Treatments for macular degeneration: summarising evidence using network meta-analysis. Br J Ophthalmol. doi:10.1136/bjophthalmol-2011-300316
  7. 7.
    Passaro D, Fadda V, Maratea D, Messori A (2011) Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. Int J Cardiol 150(3):364–367Google Scholar
  8. 8.
    Maratea D, Fadda V, Trippoli S, Messori A (2011) Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 9(9):1868–1870Google Scholar
  9. 9.
    Cohen D (2011) NICE rules out NHS prescription of fingolimod for multiple sclerosis. Br Med J 343:d5117CrossRefGoogle Scholar
  10. 10.
    NICE. Fingolimod: appraisal consultation–evaluation report. Available at: http://guidance.nice.org.uk/TA/Wave20/71/Consultation/Latest. Accessed 1 Oct 2011
  11. 11.
    Freedman MS (2011) Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76(1 Suppl 1):S26–S34PubMedCrossRefGoogle Scholar
  12. 12.
    Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, Gray R (2009) Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. Br Med J 339:b4677. doi:10.1136/bmj.b4677 CrossRefGoogle Scholar
  13. 13.
    Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, Al-Sabbagh A, Meletiche DM (2009) Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. PharmacoEconomics 27(1):39–53PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Fabiola Del Santo
    • 1
  • Dario Maratea
    • 1
  • Valeria Fadda
    • 1
  • Sabrina Trippoli
    • 1
  • Andrea Messori
    • 1
  1. 1.Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro ToscanaRegional Health SystemPratoItaly

Personalised recommendations